Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) co ...

中概股，继续大涨。 当地时间7月23日，美股三大指数集体高开，但纳指随后一度翻绿，截至发稿，道指涨0.5%，纳指微涨 0.07%，标普500指数涨0.27%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | DJI | 道琼斯工业指数 | 44723.24 | 220.80 | 0.50% | | IXIC | 纳斯达克指数 | 20908.24 | 15.55 | 0.07% | | SPX | 标普500 | 6326.52 | 16.90 | 0.27% | 个股方面，法国生物技术公司Abivax一度大涨近600%，此前该公司报告了其口服溃疡性结肠炎治疗药物 在后期试验中取得了强劲成果。 此外，随着华尔街投机情绪升温，继百货公司股科尔士百货 、房地产科技公司OpenDoor受到散户投资 者追捧之后，甜甜圈连锁品牌 Krispy Kreme 、运动相机制造商 GoPro 等加入 "迷因股（Meme股，通常 指散户抱团股）" 狂欢。 中概股继续强势，纳斯达克中国金龙指数一度涨近1.4%。宏利营造一度涨超100%，脑再生一度涨超 30 ...

一则利好消息突然引爆。 7月23日晚间，美股开盘后，生物技术公司Abivax股价一度暴涨超596%。该公司宣布，口服新药Obefazimod在 溃疡性结肠炎III期诱导试验中取得积极结果，并计划2026年下半年向美国食品药品监督管理局（FDA）提交申 请。 值得注意的是，在美股散户投资者疯狂爆炒"网红股"的背景下，多家华尔街机构发出警告称，预计美股市场将 很快回调。其中，高盛、Evercore ISI、Stifel、太平洋投资管理公司和汇丰银行等机构表示，美股短期存在调 整的风险。 突然暴涨 北京时间7月23日晚间，美股三大指数集体高开，随后窄幅震荡，截至22:50，道指涨0.43%，纳指涨0.11%，标 普500指数涨0.28%。 热门股方面，在美股上市的法国生物技术公司Abivax股价盘初一度暴涨超596%，截至券商中国记者发稿，涨 幅仍高达560%。 消息面上，Abivax宣布，其首创新型口服miR-124增强剂Obefazimod在中度至重度溃疡性结肠炎的ABTECT 8 周诱导试验中取得积极的III期结果。公司还称，准备在2026年下半年向FDA提交新药申请。 有分析称，Abivax有望成为美股创新 ...

中概股，继续大涨。 当地时间7月23日，美股三大指数集体高开，但纳指随后一度翻绿，截至发稿，道指涨0.5%，纳指微涨 0.07%，标普500指数涨0.27%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | DJI | 道琼斯工业指数 | 44723.24 | 220.80 | 0.50% | | IXIC | 纳斯达克指数 | 20908.24 | 15.55 | 0.07% | | SPX | 标普500 | 6326.52 | 16.90 | 0.27% | 个股方面，法国生物技术公司Abivax一度大涨近600%，此前该公司报告了其口服溃疡性结肠炎治疗药物 在后期试验中取得了强劲成果。 此外，随着华尔街投机情绪升温，继百货公司股 科尔士百货 、房地产科技公司OpenDoor受到散户投资者 追捧之后，甜甜圈连锁品牌 Krispy Kreme 、运动相机制造商 GoPro 等加入 "迷因股 （Meme股，通常指 散户抱团股） " 狂欢。 中概股继续强势，纳斯达克中国金龙指数一度涨近1.4%。宏利营造一度涨超100%，脑再生一度涨超 ...

ABTECT Phase 3 Topline Readout – Analyst and Investor Webcast July 22nd, 2025 Agenda 2 3 This presentation contains information pertaining to Abivax SA ("Abivax," the "Company," "we," "our" or "us"). Joseph B Kirsner Professor In Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Director, Inflammatory Bowel Disease Center Forward Looking Statements David Rubin, MD David T. Rubin, MD, is a renowned gastroenterologist whose work is focused on new clinical trial designs, novel measures and ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis 50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a plac ...

Group 1 - The core focus of Abivax is on developing therapeutics that modulate the inflammatory response in patients with chronic inflammatory diseases [1][3] - The annual general meeting of shareholders was held on June 6, 2025, chaired by Sylvie Grégoire [1][2] - All resolutions proposed by the Board were adopted, including the financial statements for the 2024 financial year and the compensation policy for key executives [2] Group 2 - Sylvie Grégoire was ratified as Chairman, and Dominik Höchli, MD, was appointed as a Board member [2] - Abivax's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis [3]

Core Viewpoint - Abivax SA reported its financial results for the first quarter of 2025, highlighting a decrease in total operating income and an increase in operating loss, primarily driven by rising research and development expenses [2][3][7]. Financial Highlights - Total operating income for Q1 2025 was €1.0 million, down from €1.2 million in Q1 2024, reflecting a decrease of €0.2 million [3][7]. - Total operating expenses increased, with research and development costs rising to €39.3 million from €35.7 million, an increase of €3.6 million [3][7]. - The operating loss for the quarter was €47.2 million, compared to €44.7 million in the same period last year, marking an increase of €2.5 million [3][7]. - The net loss for the period was €52.4 million, up from €42.9 million in Q1 2024, indicating a rise of €9.5 million [3][7]. Balance Sheet Overview - As of March 31, 2025, the net financial position was €18.5 million, a decrease of €34.9 million from €53.4 million at the end of 2024 [3][5]. - Cash and cash equivalents stood at €103.6 million, down from €144.2 million at the end of 2024, reflecting a decrease of €40.6 million [5][7]. - Total assets decreased to €166.9 million from €205.2 million, a reduction of €38.3 million [5]. Research and Development Focus - R&D expenses increased significantly, with a €3.0 million (736%) rise related to the Crohn's Disease clinical program, driven by the progression of Phase 2b clinical trials for obefazimod [7]. - A €2.7 million (78%) increase in transversal activities was noted, attributed to the expansion of the R&D headcount and new equity awards [7]. - There was a decrease of €1.3 million (-4%) in expenses related to the Ulcerative Colitis clinical program as Phase 3 trials reached full enrollment [7]. Operational Updates - Abivax is focused on developing therapeutics for chronic inflammatory diseases, with its lead drug candidate, obefazimod, currently in Phase 3 clinical trials for ulcerative colitis [2][8]. - The company anticipates being able to finance its operating cash flow requirements into the fourth quarter of 2025 based on current funds and operating assumptions [6].

Core Viewpoint - Abivax has completed enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis, marking a significant milestone for the company and the patient community [2][3]. Group 1: Trial Enrollment and Characteristics - A total of 1,275 participants were successfully enrolled in the Phase 3 ABTECT trials, exceeding the target enrollment of 1,224 by 4% [6]. - The blinded baseline characteristics of participants in the Phase 3 ABTECT trials closely align with those observed in the Phase 2b trial, reinforcing confidence in the drug's potential efficacy and safety [3][9]. - Key baseline characteristics include: - 65% of participants had a baseline MMS score of 7-9 in Phase 3 compared to 71% in Phase 2b - 48% had prior advanced therapy in both trials - 42% of Phase 3 participants had previously failed corticosteroid treatment, compared to 52% in Phase 2b [3][6]. Group 2: Upcoming Milestones - Top-line results from the 8-week induction trials are anticipated in Q3 2025, with 44-week maintenance data expected in Q2 2026 [6][9]. - If the results confirm the safety and efficacy of obefazimod, a New Drug Application (NDA) submission to the FDA is planned for the second half of 2026 [3][9]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [7]. - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [7].

Core Points - Abivax is advancing towards key operational milestones in 2025, including the ongoing Phase 3 ABTECT clinical program [3][7] - The Annual General Meeting is scheduled for June 6, 2025, in Paris, France [1][7] - The company aims to complete enrollment for induction trials in Q2 2025, with top-line data expected in Q3 2025 [3][7] - The CEO of Abivax, Marc de Garidel, expressed confidence in the company's long-term value, highlighting a personal investment of approximately 120,000 shares in Q1 2025 [4] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases [5] - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 trials for moderately to severely active ulcerative colitis [5]